ダウンロード数: 299
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
bjophthalmol-2018-311963.pdf | 378.89 kB | Adobe PDF | 見る/開く |
タイトル: | Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy |
著者: | Miyata, Manabu https://orcid.org/0000-0002-7574-1749 (unconfirmed) Ooto, Sotaro Yamashiro, Kenji Tamura, Hiroshi https://orcid.org/0000-0002-7740-2732 (unconfirmed) Hata, Masayuki Ueda-Arakawa, Naoko Yoshikawa, Munemitsu Numa, Shogo Tsujikawa, Akitaka |
著者名の別形: | 宮田, 学 大音, 壮太郎 山城, 健児 田村, 寛 畑, 匡侑 上田, 奈央子 吉川, 宗光 沼, 尚吾 辻川, 明孝 |
発行日: | May-2019 |
出版者: | BMJ Publishing Group |
誌名: | British Journal of Ophthalmology |
巻: | 103 |
号: | 5 |
開始ページ: | 617 |
終了ページ: | 622 |
抄録: | [Background/aims] To evaluate the 5-year visual and anatomical outcomes after anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with photodynamic therapy (PDT), followed by pro re nata (PRN) anti-VEGF therapy with or without PDT, for polypoidal choroidal vasculopathy (PCV). [Methods] This retrospective, observational study included 61 consecutive patients with treatment-naïve symptomatic PCV who were followed for 5 years. Twenty eyes (20 patients) initially received PDT and intravitreal injection of ranibizumab (IVR), followed by a PRN regimen of anti-VEGF therapy with or without PDT (combination group), while 41 eyes (41 patients) initially received only IVR every 3 months, followed by a PRN regimen of anti-VEGF monotherapy (IVR group). Macular atrophy including the fovea was confirmed using colour fundus photography and spectral-domain optical coherence tomography. [Results] In both groups, the visual acuity (VA) at 1 year was better than the baseline VA, whereas the 3-year, 4-year and 5-year VA values were similar to the baseline VA. There was no significant difference in the 5-year VA, 5-year central retinal thickness and incidence of macular atrophy between the two groups (p=0.63, 0.72 and 0.06, respectively). In the combination group, the 5-year VA was correlated with the 5-year incidence of macular atrophy (p=0.02, r=0.51). [Conclusions] A PRN regimen for PCV may have a limited effect for the long-term maintenance of improved VA. Macular atrophy may occur more frequently with combination therapy and is possibly associated with the 5-year VA. Thus, combination therapy should be carefully selected for patients susceptible to macular atrophy. |
著作権等: | This article has been accepted for publication in 'British Journal of Ophthalmology' following peer review. The definitive copyedited, typeset version Miyata M, Ooto S, Yamashiro K, et al. Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. British Journal of Ophthalmology 2019;103:617-622. is available online at: https://bjo.bmj.com/content/early/2018/09/29/bjophthalmol-2018-311963 This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/235951 |
DOI(出版社版): | 10.1136/bjophthalmol-2018-311963 |
PubMed ID: | 29875231 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。